Literature DB >> 6149131

Tetrabenazine-induced depletion of brain monoamines: mechanism by which desmethylimipramine protects cortical norepinephrine.

D J Pettibone, A B Pflueger, J A Totaro.   

Abstract

Pretreatment of rats with desmethylimipramine (DMI) (5 mg/kg) significantly antagonized the tetrabenazine (TBZ)-induced (3 mg/kg) depletion of cortical norepinephrine (NE) in rats. This protective effect of DMI was fully blocked by the specific alpha 2-adrenergic antagonist, RX 781094. The doses of DMI which antagonized the depleting effects of TBZ caused rapid, maximal reductions in cortical dihydroxyphenylalanine (DOPA) accumulation, effects which were also blocked by RX 781094. Like DMI, the alpha 2-adrenergic agonist, clonidine (50 micrograms/kg) decreased cortical DOPA accumulation and rapidly prevented the TBZ-evoked loss of NE in this brain region. On the other hand, doses of RX 781094 (0.5-2.0 mg/kg) which accelerated cortical DOPA synthesis, enhanced significantly the depleting effects of a threshold dose of TBZ (0.6 mg/kg). These findings suggest that DMI reduces the rate of TBZ-induced depletion of cortical NE by lowering NE turnover through the indirect stimulation of alpha 2-adrenoceptors.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6149131     DOI: 10.1016/0014-2999(84)90563-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

1.  Tetrabenazine: for chorea associated with Huntington's disease.

Authors:  Lesley J Scott
Journal:  CNS Drugs       Date:  2011-12-01       Impact factor: 5.749

2.  Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators.

Authors:  Samuel Frank
Journal:  BMC Neurol       Date:  2009-12-18       Impact factor: 2.474

3.  Synthesis of H-Labeled Tetrabenazine (TBZ).

Authors:  Sung-Whi Rhee; Kenneth J Ryan; Mary J Tanga
Journal:  J Labelled Comp Radiopharm       Date:  2011-06-15       Impact factor: 1.921

Review 4.  Functional Differences Between Direct and Indirect Striatal Output Pathways in Huntington's Disease.

Authors:  Laurie Galvan; Véronique M André; Elizabeth A Wang; Carlos Cepeda; Michael S Levine
Journal:  J Huntingtons Dis       Date:  2012

5.  Tetrabenazine in treatment of hyperkinetic movement disorders: an observational study.

Authors:  Rita Miguel; Marcelo D Mendonça; Raquel Barbosa; Filipa Ladeira; Tânia Lampreia; José Vale; Paulo Bugalho
Journal:  Ther Adv Neurol Disord       Date:  2016-11-21       Impact factor: 6.570

6.  The thermogenic actions of alpha 2-adrenoceptor agonists in reserpinized mice are mediated via a central postsynaptic alpha 2-adrenoceptor mechanism.

Authors:  D J Bill; I E Hughes; R J Stephens
Journal:  Br J Pharmacol       Date:  1989-01       Impact factor: 8.739

Review 7.  Vesicular monoamine transporter 2: role as a novel target for drug development.

Authors:  Guangrong Zheng; Linda P Dwoskin; Peter A Crooks
Journal:  AAPS J       Date:  2006-11-10       Impact factor: 4.009

Review 8.  Treatment of Huntington's disease.

Authors:  Samuel Frank
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 9.  Advances in the pharmacological management of Huntington's disease.

Authors:  Samuel Frank; Joseph Jankovic
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

10.  Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease.

Authors:  Samuel Frank
Journal:  Neuropsychiatr Dis Treat       Date:  2010-10-05       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.